Revolution Medicines, Inc.（RVMD）今日盘中股价大涨5.07%，表现强劲。
消息面上，公司核心实验性口服药物daraxonrasib在针对既往接受过治疗的胰腺癌患者的III期临床试验中取得了积极成果。数据显示，该药物将患者的中位总生存期延长至13.2个月，而化疗对照组仅为6.7个月，生存期提升近一倍。公司已计划就此数据向美国食品药品监督管理局（FDA）寻求审查。
这一突破性数据显著降低了该药物研发项目的风险，并被视为胰腺癌治疗领域的潜在“游戏规则改变者”。包括RBC Capital Markets、Wedbush、Evercore ISI和Jefferies在内的多家知名券商随后发布了积极观点，给予“跑赢大盘”或“买入”评级，目标价设定在140美元至147美元之间，进一步强化了市场对公司商业化前景的信心，从而推动了股价在盘中的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.